Comparison of hplc, tlc and minicolumn for measuring the radiochemical purity of 99tcm-q12

Meixiang Max Yu; K. A. BergstrÖM; J. T. Kuikka; J. Yang; E. Vanninen

doi:10.1080/00006231-199805000-00012

Comparison of hplc, tlc and minicolumn for measuring the radiochemical purity of ⁹⁹tc^m-q12

Meixiang Max Yu, K. A. BergstrÖM, J. T. Kuikka, J. Yang, E. Vanninen

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

TechneScan Q12® (⁹⁹Tc(m)-Q12) is a new agent for clinical myocardial perfusion imaging. A product with high radiochemical purity is essential for high-quality imaging. We compared three methods of radiochemical purity analysis for ⁹⁹Tc(m)-Q12: thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC) and minicolumn. Thin-layer chromatography resulted in lower purity (87 ± 8%) than the minicolumn method (aluminium oxide minicolumn, ethanol) (95 ± 4%). The HPLC method resulted in the lowest purity (79 ± 11%). The main impurity was a polar compound, but three further impurities were found using HPLC. Using HPLC, we found the percentage of the parent compound (⁹⁹Tc(m)-Q12) in plasma at 40-90 min post-injection to be 19.3 ± 6.2%. We suggest that gradient HPLC is the most effective method for the analysis of the radiochemical purity of ⁹⁹Tc(m)-Q12, and that it can be used to determine the concentration of ⁹⁹Tc(m)-Q12 in plasma.

Original language	English (US)
Pages (from-to)	483-489
Number of pages	7
Journal	Nuclear medicine communications
Volume	19
Issue number	5
DOIs	https://doi.org/10.1080/00006231-199805000-00012
State	Published - Jan 1 1998

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1080/00006231-199805000-00012

Cite this

@article{0e692088818349b3819960b79602083f,

title = "Comparison of hplc, tlc and minicolumn for measuring the radiochemical purity of 99tcm-q12",

abstract = "TechneScan Q12{\textregistered} (99Tc(m)-Q12) is a new agent for clinical myocardial perfusion imaging. A product with high radiochemical purity is essential for high-quality imaging. We compared three methods of radiochemical purity analysis for 99Tc(m)-Q12: thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC) and minicolumn. Thin-layer chromatography resulted in lower purity (87 ± 8%) than the minicolumn method (aluminium oxide minicolumn, ethanol) (95 ± 4%). The HPLC method resulted in the lowest purity (79 ± 11%). The main impurity was a polar compound, but three further impurities were found using HPLC. Using HPLC, we found the percentage of the parent compound (99Tc(m)-Q12) in plasma at 40-90 min post-injection to be 19.3 ± 6.2%. We suggest that gradient HPLC is the most effective method for the analysis of the radiochemical purity of 99Tc(m)-Q12, and that it can be used to determine the concentration of 99Tc(m)-Q12 in plasma.",

author = "Yu, {Meixiang Max} and Bergstr{\"O}M, {K. A.} and Kuikka, {J. T.} and J. Yang and E. Vanninen",

year = "1998",

month = jan,

day = "1",

doi = "10.1080/00006231-199805000-00012",

language = "English (US)",

volume = "19",

pages = "483--489",

journal = "Nuclear medicine communications",

issn = "0143-3636",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Comparison of hplc, tlc and minicolumn for measuring the radiochemical purity of 99tcm-q12

AU - Yu, Meixiang Max

AU - BergstrÖM, K. A.

AU - Kuikka, J. T.

AU - Yang, J.

AU - Vanninen, E.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - TechneScan Q12® (99Tc(m)-Q12) is a new agent for clinical myocardial perfusion imaging. A product with high radiochemical purity is essential for high-quality imaging. We compared three methods of radiochemical purity analysis for 99Tc(m)-Q12: thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC) and minicolumn. Thin-layer chromatography resulted in lower purity (87 ± 8%) than the minicolumn method (aluminium oxide minicolumn, ethanol) (95 ± 4%). The HPLC method resulted in the lowest purity (79 ± 11%). The main impurity was a polar compound, but three further impurities were found using HPLC. Using HPLC, we found the percentage of the parent compound (99Tc(m)-Q12) in plasma at 40-90 min post-injection to be 19.3 ± 6.2%. We suggest that gradient HPLC is the most effective method for the analysis of the radiochemical purity of 99Tc(m)-Q12, and that it can be used to determine the concentration of 99Tc(m)-Q12 in plasma.

AB - TechneScan Q12® (99Tc(m)-Q12) is a new agent for clinical myocardial perfusion imaging. A product with high radiochemical purity is essential for high-quality imaging. We compared three methods of radiochemical purity analysis for 99Tc(m)-Q12: thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC) and minicolumn. Thin-layer chromatography resulted in lower purity (87 ± 8%) than the minicolumn method (aluminium oxide minicolumn, ethanol) (95 ± 4%). The HPLC method resulted in the lowest purity (79 ± 11%). The main impurity was a polar compound, but three further impurities were found using HPLC. Using HPLC, we found the percentage of the parent compound (99Tc(m)-Q12) in plasma at 40-90 min post-injection to be 19.3 ± 6.2%. We suggest that gradient HPLC is the most effective method for the analysis of the radiochemical purity of 99Tc(m)-Q12, and that it can be used to determine the concentration of 99Tc(m)-Q12 in plasma.

UR - http://www.scopus.com/inward/record.url?scp=0031747926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031747926&partnerID=8YFLogxK

U2 - 10.1080/00006231-199805000-00012

DO - 10.1080/00006231-199805000-00012

M3 - Article

C2 - 9853339

AN - SCOPUS:0031747926

VL - 19

SP - 483

EP - 489

JO - Nuclear medicine communications

JF - Nuclear medicine communications

SN - 0143-3636

IS - 5

ER -

Comparison of hplc, tlc and minicolumn for measuring the radiochemical purity of ⁹⁹tc^m-q12

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this